He said that after getting injected with the third dose of the COVID-19 Vaccine (Pfizer) he experienced severe melting of the ...

Is cancer the next big thing for pharma giants? Pfizer CEO has said that since the COVID-19 pandemic is over and global ...

Andrew Baum, the prominent Wall Street drug company analyst will be the pharma firm’s chief strategy and innovation officer.

Andrew Baum has worked at Citi since 2011 following a 14-year stint at Morgan Stanley, where he covered European ...

Additionally, BioNTech’s diluted earnings per share dropped from €2.05 in Q1 2023 to a net loss per share of €1.31. Beyond the topline results, BioNTech’s quarterly R&D expenses totaled €507.5 million ...

Cell and gene therapy company Cellectis announced Monday it has completed a $140 million investment from AstraZeneca that ...

Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio ...

BioNTech's long-term outlook helped it shrug off a first-quarter loss and sinking revenue as demand for COVID-19 vaccines ...

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the ...

AM Best has confirmed the financial strength rating of A (Excellent) and the long-term issuer credit rating of a+ (Excellent) ...

Pfizer's strategic weaknesses mount and the stock became overvalued after the recent rally. Read more to see our analysis on ...

The company specializes in donor-derived, or “allogeneic” cell therapies for cancer, and over the years has forged partnerships with fellow French drugmaker Servier as well as U.S.-based Pfizer ...